奥浦迈股价跌5.05%，工银瑞信基金旗下1只基金位居十大流通股东，持有290.01万股浮亏损失777.22万元

Group 1 - The core viewpoint of the news is that Aopumai's stock price has decreased by 5.05%, currently trading at 50.37 CNY per share, with a total market capitalization of 5.719 billion CNY [1] - Aopumai Biotechnology Co., Ltd. was established on November 27, 2013, and went public on September 2, 2022. The company specializes in cell culture products and services, with revenue composition being 87.34% from products, 12.53% from services, and 0.13% from other sources [1] - The trading volume for Aopumai was 64.8416 million CNY, with a turnover rate of 1.10% [1] Group 2 - Among Aopumai's top ten circulating shareholders, a fund under ICBC Credit Suisse Asset Management has increased its holdings by 1.2508 million shares, totaling 2.9001 million shares, which represents 3.75% of the circulating shares [2] - The fund, ICBC Credit Suisse Frontier Medical Stock A (001717), has a current scale of 9.33 billion CNY and has achieved a year-to-date return of 41.51%, ranking 537 out of 4222 in its category [2] - The fund manager, Zhao Bei, has a tenure of nearly 11 years, with the fund's best return during this period being 275.3% and the worst being -24.35% [2]